Background: Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, caused by quantitative and qualitative changes in von Willebrand factor (VWF). The biology of VWD, studied in canine, porcine, and murine models, differ in species-specific biology of VWF and the amenability to experimental manipulations such as phlebotomy. The factor VIII (FVIII) levels in these models are higher than in humans with type 3 VWD, suggesting functional differences between FVIII and VWF.
| INTRODUCTION
Von Willebrand disease (VWD) is a common inherited bleeding disorder in humans. The causes of VWD are abnormalities in the quantity or functional quality of von Willebrand factor (VWF). Severe or type 3 VWD in humans is characterized by having undetectable levels of VWF protein and activity as well as very low levels of factor VIII (FVIII) clotting factors (1-9 IU/dL) and is caused by a homozygous deficiency of VWF. 1 The prevalence of type 3 VWD is estimated as 1.38 per million population in North America. 1 Clinical manifestations of type 3 VWD include frequent epistaxis, ecchymoses, intracranial hemorrhage, prolonged bleeding after trauma or surgery, excessive menorrhagia or postpartum hemorrhage in women, and spontaneous joint and muscle bleeds. 2 VWF has several key functions in hemostasis. One of these functions is to stabilize FVIII in circulation by FVIII binding to the D′ and D3 regions of VWF. VWF's interaction with FVIII is necessary to prevent the rapid clearance of FVIII from the circulation. 3 Humans with type 3 VWD have undetectable levels of VWF and consequently very low levels of FVIII by virtue of the rapid clearance of FVIII in the absence of VWF. VWF also has 2 distinct binding sites for collagen in VWF's A1 (collagen IV and VI) and A3 (collagen I and III) domains 4,5 that mediate VWF binding to exposed subendothelial collagen, whereas the interaction of platelet glycoprotein Ib-α (GPIbα) complex with the VWF A1 domain facilitates the capture of circulating platelets at sites of injury. 6 In animal models, the function of VWF has mainly been studied in canine, porcine, and murine models of severe VWD. 7 Canine VWD models have similar clinical symptoms to humans with mucosal and cutaneous bleeding, 8 but in contrast to humans, normal dogs lack platelet VWF. 9 The FVIII activity levels in the type 3 VWD canine models varies from 15% to 50% of normal dog VWF. 7 The type 3 VWD porcine model exhibits residual levels of VWF but mimics human disease with respect to bleeding time and distribution of VWF in endothelial cells and platelets, 10 yet FVIII activity remains at about 30% of normal pig VWF. 6 Further limitations of the porcine model include the logistic requirements for the housing of large numbers of animals, and genetic heterogeneity of the breeding stock. The mouse model of type 3 VWD was generated by insertional disruption of intron 5 of the mouse VWF gene, shows undetectable residual VWF, and closely mimics laboratory findings presented in human disease. 11 Like the canine and dog models of type 3 VWD, the FVIII activity level of the type 3 murine model is 20% of normal mouse VWF. 7 While VWF -/mice are easily maintained and exhibit a homogeneous genetic background, their small size limits the spectrum of analytical and experimental interventions.
In the current study, we developed and characterized a novel rat model of severe type 3 VWD by CRISPR/Cas9-mediated elimination of all 52 exons of the rat VWF locus. Furthermore, the heterozygous rats exhibit an intermediate phenotype as seen in humans as well.
| METHODS

| Generation of VWF knockout rat
Studies were approved by the Animal Care and Use Committee of the Medical College of Wisconsin. The VWF knockout (KO) (SD-Vwf em1Mcwi ) rat or VWF -/was developed by CRISPR/Cas9-mediated elimination of the entire VWF gene. CRISPR target sequences flanking exon 1 and 52, respectively were identified using the MIT CRISPR Design Tool (Zhang Lab, Cambridge, MA, USA). 12 Paired oligonucleotides (upstream exon 1:5'-CCTCGGTAATTAAGAGAAGGCC-3'; downstream exon 52:5'-CCCTCCTGGGCCCACAATAAAGG-3') were synthesized by Thermo Fisher (Waltham, MA, USA), annealed, and cloned into the pX459 plasmid at the Bbsl site. 13 The 2 plasmids containing 5′ and 3′ CRISPR guide sequences, respectively, were coinjected into 1 cell-stage Sprague-Dawley (Crl:SD) rat embryos.
Resulting offspring were screened for the desired VWF gene deletion by PCR analysis of genomic DNA (gDNA) purified from white blood cell (WBC) pellets using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). The 5′ end PCR product of the VWF gene (502 bp) was identified using VWF 5′ F primer (ttcatacctgtgggtgacgg) and VWF 5′ R primer (ctggatggatctgctcaggc). The 3′ end PCR product of the VWF gene (450 bp) was identified using VWF 3′ F primer (cggcagactcctactgctac) and the VWF 3′ R primer (ctgatttccagagcccacct). The deletion PCR product of the region flanking the VWF gene (673 bp) was identified using the VWF 5′ F primer and VWF 3′ R primer ( Figure 1 ). Founder animals were mated with a wild-type (WT) SD rats to produce heterozygous offspring that were used to generate homozygous offspring with no expression of VWF.
| Blood draws and preparation of plasma
Whole blood (0.5 mL) was obtained from the ventral tail artery at 6 to 10 weeks of age using a 25G needle and 1-mL syringe containing 4% sodium citrate (10% of final volume). Whole blood was centrifuged at 2300 g for 10 minutes. The plasma was then recentrifuged at 9300 g for 10 minutes to obtain platelet-poor plasma (PPP). PPP was aliquoted and frozen at −80˚C or used immediately for assays.
| ELISA
Rat VWF antigen (VWF:Ag) levels were measured by ELISA. The reference standard for all assays was a pool of plasma obtained from nine Sprague-Dawley wild-type rats and frozen in small aliquots.
Immulon 1B plates (Thermo Scientific, Waltham, MA, USA) were coated with anti-VWF capture antibody 344.1 (Blood Research Institute, Milwaukee, WI, USA) diluted to 2.5 µg/mL in carbonate coating buffer (CCB; 0.015M NaCO 3 and 0.035M NaHCO 3 , pH 9.5).
Plates were blocked with 1% BSA in phosphate-buffered saline (PBS).
Rat VWF samples and standard were diluted in the same blocking buffer as above, loaded 50 µL in triplicate on the ELISA plate, and incubated for 1 hour at room temperature. Detection of bound VWF was measured using a biotinylated polyclonal anti-VWF antibody (Dako, Dako Denmark) diluted to 2 µg/mL in blocking buffer.
Rat VWF propeptide was measured by ELISA using antibodies To generate a rat-specific VWF propeptide antibody, VWF-/-mice were immunized with nickel purified recombinant rat VWF propeptide as previously described. 14 Blood samples were diluted with modified Tyrode's buffer and centrifuged at 200 g for 2 minutes at room temperature to collect platelet-rich plasma (PRP). PRP was counted for platelets and was then transferred to a fresh 1.5-mL tube and spun down at 900 g for 20 minutes to obtain a platelet pellet. PBS containing 0.5%
3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate was
added to the platelet pellet for lysis. Samples were then spun at 16 100 g at 4˚C for 10 minutes to obtain cleared lysates.
| Gel electrophoresis
Multimer distribution was examined by gel electrophoresis as previously described 15 using a polyclonal anti-VWF antibody described above.
| FVIII chromogenic assay
Plasma FVIII in VWF -/rats was determined by FVIII chromogenic activity assay (FVIII:C) using a COATEST SP4 FVIII kit (Chromogenix, Bedford, MA, USA). Plasma was diluted in 1x F I G U R E 1 Deletion of von Willebrand factor (VWF) gene by CRISPR/Cas9. Two guide RNAs (gRNA) with protospacer-adjacent motif (PAM) were designed to cut at the 5′ and 3′ end to flank the entire coding sequence of the VWF gene. The 5′ end of the VWF gene (502 bp) was identified using the VWF 5′ F primer (VWF5F) and VWF 5′ R primer (VWFWTR). The 3′ end of the VWF gene (450 bp) was identified using the VWF 3′ F primer (VWFWTF) and VWF 3′ R primer (VWFDELR). The deletion of the regions flanking the VWF gene PCR product (673 bp) was identified using the VWF 5′ F primer (VWF5F) and the VWF 3′ R primer (VWFDELR). Rat reference sequence is from NCBI RefSeq, Accession NW 001 084 832 
| Transected lateral tail vein bleeding assay
To assess the bleeding phenotype, 20-to 24-week-old anesthetized rats (both male and female) were placed in a device that allowed us to measure the location where the diameter of the tail was 6.4 mm.
The tail was marked and then placed in a second device that allowed us to make a cut across the lateral tail vein that was 2.0 mm in depth. After the lateral tail vein was transected, it was placed in 45 mL of prewarmed 37˚C distilled water in a 50-mL graduated cylinder for 10 minutes, causing red blood cell (RBC) lysis as bleeding occurred. Bleeding time was recorded when the stream of blood was no longer visible. To determine the amount of blood lost, hemoglobin was quantified from RBC lysis by pipetting 50 µL of the collected blood in distilled water into the wells of an Immulon 1B plate (Thermo Scientific, Waltham, MA, USA) and the absorbance was measured at 575 nm. Dilutions of pooled fresh whole blood from 4
WT rats were prepared in distilled water as a standard curve.
| Transfusion with FVIII-deficient PPP
Whole blood was collected into 4% citrate (10% of final volume) using a 25G butterfly needle from the inferior vena cava of Sprague-Dawley FVIII -/rats. 17 PPP was prepared as described above. About 10 mL/ kg of pooled FVIII-deficient PPP was infused into the lateral tail vein of VWF -/rats. Sequential blood draws (0.2 mL) in each rat from the tail artery for analysis of VWF:Ag and FVIII:C were obtained at the following time points: 0, 0.5, 2, 6, 12, 24, 36, and 48 hours.
| Recombinant human VWF infusion
Recombinant human VWF (Vonvendi; Shire, Lexington, MA, USA) was infused at 100 to 200 U/kg in the lateral tail vein of VWF -/rats.
Sequential blood draws (0.2 mL) in each rat from the tail artery for analysis of VWF:Ag and FVIII:C were obtained at the following time points: 0, 0.5, 1, 2, 4, 6, 12, and 24 hours.
| Statistical analysis
Differences between rat genotypes were examined using a Mann- The 95% confidence interval was estimated based on t-distribution.
The software used was an R program PK.
| RESULTS
| Generation of VWF KO rats
Of 17 pups born, 11 carried insertions/deletions at the predicted 5′ and/or 3′ guide RNA target site, as judged from surveyor assays.
Complete VWF gene deletion of exons 1 to 52, in 1 allele, was de- 
| VWF and FVIII assays
There was a significant difference in plasma VWF:Ag between all genotypes (P < 0.0001) with a mean of 94. Figure 2D ). Thus, similar to human type 3 VWD, VWF rats -/exhibit a profound secondary deficiency of plasma FVIII, with substantial variability of FVIII:C in WT and heterozygous rats.
| Transected lateral tail vein bleeding assay
After lateral tail vein template transection, all VWF -/rats bled for > 10 minutes, while VWF +/+ rats bled for a mean of 1.9 ± 0.8 min and VWF +/rats bled for a mean of 2.3 ± 0.4 minutes (P < 0.01; Figure 3A ). Blood loss measurement demonstrated that VWF -/rats lost greater quantities of blood loss than VWF +/+ rats and VWF +/rats (P < 0.01). Blood loss mean for VWF -/rats was 5.1 ± 1.7 mL, in VWF +/rats was 1.1 ± 0.9 mL, and in VWF +/+ rats was 0.4 ± 0.6 mL ( Figure 3B ). These data documented that VWF -/rats exhibited increased bleeding time and blood loss following injury.
| Endogenous production of FVIII in VWF-/-rats
In order to ascertain rat VWF chaperone function for FVIII to prevent rapid clearance of endogenous FVIII, we infused com- 
| Interaction of human VWF with rat FVIII
| DISCUSSION
In this study, we established a novel rat model of severe VWD by eliminating the full 52 exons of the VWF gene locus using In the VWF -/-SD rat, FVIII levels were below the LOD of 1.6%, closely resembling the levels of 1% to 5% measured in patients with type 3 VWD.
Given that more than half of SD rats with complete FVIII deficiency (FVIII -/-) have been reported to develop spontaneous joint bleeding requiring therapeutic intervention, 17 the very low FVIII levels in the VWF -/-SD rat nevertheless seem sufficient to sustain normal hemostasis in the absence of major challenges. Humans with severe VWD not only are prone to spontaneous mucocutaneous bleeds but also may develop soft tissue bleeds and hemarthroses, which have been attributed to low FVIII levels. We therefore suspect that the conspicuous absence of spontaneous bleeding episodes in type 3 VWD animal models predominantly reflects a higher threshold for the minimum FVIII level required for sustaining near-normal hemostasis in humans. On the other hand, future studies will be required to determine whether additional factors such as increased physical activity, age, or hormone replacement therapy may trigger bleeding episodes in the VWF -/rat even in the absence of experimentally provoked injury.
Patients with type 3 VWD who are infused with completely deficient FVIII plasma (as a source of VWF) show a progressive increase of FVIII in the circulation followed by a decay phase as the infused VWF is cleared from the circulation. For example, in 8 human subjects infused with human VWF without FVIII, the FVIII:C plasma levels increased progressively with a peak at 24 hours after infusion followed by a gradual decay. 18 Likewise, infusion of human recombinant VWF into human subjects with severe VWD revealed a VWF:Ag half-life of 21.9 hours, and a substantial stabilization of endogenous FVIII:C, peaking at 24 hours after infusion. 19 In the canine model of severe VWD, infusion of human recombinant VWF resulted in a VWF:Ag halflife of 21.6 hours in one dog and 22.1 hours in a second dog with sustained increases in endogenous FVIII levels. 8 In our previous study, we showed that FVIII levels in mouse plasma could be restored up to 800 mU/mL when human recombinant VWF was infused into VWF (null) mice either by intravenous or intraperitoneal administration. 20 Although these data were not directly from a VWF/FVIII binding assay, it indicated that human VWF can bind to mouse FVIII and stabilize endogenous murine FVIII in plasma of VWF (null) mice. In marked contrast, infusion of high doses of human recombinant VWF in the VWF -/rats resulted in quick clearance of VWF:Ag with a half-life of approximately 2 hours and an initial small rise in endogenous rat FVIII. We find there is 1 to 3 IU of FVIII per 100 IU of VWF, so the small rise in FVIII is probably due to minimal amounts of rat FVIII and residual FVIII in the human recombinant VWF. Since infusion of exogenous rat VWF present in rat FVIII -/-PPP leads to measurable amounts of endogenous FVIII with the FVIII:C peaking at 6 hours in the VWF -/-SD rat, the discrepancy between the SD rat on the one hand and humans and other species on the other hand in all likelihood reflects a species-specific inability of human VWF to interact with rat FVIII. This feature might be exploited to study the interaction of human FVIII and VWF in an in vivo setting without interference by endogenous factors.
In summary, we have established a novel rat model of severe type 3 VWD that resembles human VWD with very low/absent VWF:Ag and minimal plasma FVIII. A second unique feature of this model is the complete elimination of the VWF gene, precluding the synthesis of any VWF-related peptide that could potentially trigger the production of alloantibodies, as suggested in humans carrying large but not complete deletions of their VWF gene. 21 The VWF -/-SD rat is amenable to a host of experimental manipulations that are difficult or near impossible to perform in other species, either for technical or logistic limitations. In addition, the large number of currently available rat genetic resources 22 should enable studies toward the identification and validation of genetic factors affecting bleeding severity and other modifying parameters of VWD.
